Feb 5 (Reuters) - GSK plc GSK.L:
GSK PLC - FINAL RESULTS
GSK: £2 BILLION SHARE BUYBACK PROGRAMME TO BE IMPLEMENTED OVER NEXT 18 MONTHS
GSK Q4 TURNOVER 8,117 MILLION POUNDS VERSUS IBES ESTIMATE 7,750 MILLION POUNDS
GSK: 2031 SALES OUTLOOK INCREASED TO MORE THAN £40 BILLION
GSK Q4 ADJUSTED EPS 23.2 P VERSUS IBES ESTIMATE 19.01 P
GSK: SALES OF MORE THAN £40 BILLION NOW EXPECTED BY 2031
GSK OUTLOOK 2025 VACCINES EXPECTED DECREASE OF A LOW SINGLE-DIGIT PER CENT IN TURNOVER
GSK: INCREASING AND PRIORITISING RESEARCH AND DEVELOPMENT INVESTMENT TO PROMISING NEW LONG-ACTING AND SPECIALTY MEDICINES
GSK - DIVIDEND 64P EXPECTED FOR 2025
Source text: ID:nRSE9111Va
Further company coverage: GSK.L